Therapeutic Advances in Infectious Disease
            
                    
                        Title Abbreviation
                        
                            Ther Adv Infect Dis
                        
                        
                     
                    
                    
                        Electronic ISSN
                        
                            2049-937X
                        
                        
                     
                    
                    
                        Readership
                        
                            Clinical Pharmacologists, Clinicians, Hospitalists, Infectious Disease Specialists, Pharmaco-Epidemiologists, Pharmacologists, Physician Assistants, Physicians, Physicians - Medicine, Researchers, Residents, Scientists
                        
                        
                     
                    
                        Scope
                        
                            Therapeutic Advances in Infectious Disease delivers the highest quality peer-reviewed open access original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of infectious diseases. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in infectious disease and related disciplines (including infection control), providing an online forum for rapid dissemination of recent research and perspectives in this area.
Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). Therapeutic Advances in infectious Disease conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees; and Online First publication is usually within 3 weeks of Acceptance.
                        
                        
                     
                    
                        Sponsoring Association(s)
                        
                            No associations affiliated with this journal
                        
                        
                     
                    
                        Publisher Name
                        
                            SAGE Publications - UK
                        
                        
                     
            
                
                    To see more details about Therapeutic Advances in Infectious Disease, 
Subscribe Now! 
                            Impact Factor
                            JCR Categories/Rank
                            Submission to Acceptance
                            Acceptance to Online Publication
                            Rejection Rate
                            Frequency
                            Journal Contact
                            Author Submission Guidelines